Luis López-Flores

Dr. Luis López-Flores

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Gene
Verified
Journal Article
Closed access
GPGloria Pérez-Rubio
Gloria Pérez-Rubio
LLLuis López-Flores
Luis López-Flores
ARAlejandra Ramírez-Venegas
Alejandra Ramírez-Venegas
VNValeri Noé-Díaz
Valeri Noé-Díaz
LGLeonor García-Gómez
Leonor García-Gómez
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia

1 February 2018 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
JRJuan Manuel Reséndiz-Hernández
Juan Manuel Reséndiz-Hernández
EAEnrique Ambrocio-Ortiz
Enrique Ambrocio-Ortiz
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
LLLuis López-Flores
Luis López-Flores
EAEdgar Abarca-Rojano
Edgar Abarca-Rojano
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
TNF promoter polymorphisms are associated with genetic susceptibility in COPD secondary to tobacco smoking and biomass burning Juan Manuel Reséndiz-Hernández,1 Enrique Ambrocio-Ortiz,1 Gloria Pérez-Rubio,1 Luis Alberto López-Flores,1 Edgar Abarca-Rojano,2 Gandhi Fernando Pavón-Romero,3 Fernando Flores-Trujillo,4 Rafael de Jesús Hernández-Zenteno,4 Ángel Camarena,1 Martha Pérez-Rodríguez,5 Ana María Salazar,6 Alejandra Ramírez-Venegas,4 Ramcés Falfán-Valencia1 1HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; 2Research and Graduate Studies Section, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico; 3Department of Allergy and Clinical Immunology, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; 4Tobacco Smoking and COPD Research Department, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico; 5Unit of Medical Research in Immunology, CMN S-XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico; 6Department of Genomic Medicine and Environmental Toxicology, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico Background: Smoking and smoke from biomass burning (BB) are the main environmental risk factors for COPD. Clinical differences have been described between COPD related to smoking and related to wood smoke, but no studies have shown genetic differences between patients exposed to these two risk factors. Methods: To investigate a possible association of tumor necrosis factor (TNF) promoter polymorphisms, we conducted a case–control study. A total of 1,322 subjects were included in four groups: patients with a diagnosis of COPD secondary to smoking (COPD-S, n=384), patients with COPD secondary to biomass burning (COPD-BB, n=168), smokers without COPD (SWOC, n=674), and biomass burning-exposed subjects (BBES n=96). Additionally, a group of 950 Mexican mestizos (MMs) was included as a population control. Three single nucleotide polymorphisms (SNPs) were selected in the TNF gene (rs1800629, rs361525, and rs1800750) and one SNP in the lymphotoxin alpha gene (rs909253). Results: Statistically significant differences were found with genotype GA of the rs1800629: COPD-S vs SWOC, (p<0.001, odds ratio [OR] =2.55, 95% CI=1.53–4.27); COPD-S vs COPD-BB (p<0.01). When performing the comparison of the less severe (G1: I + II) and the more severe (G2: III + IV) levels, differences were identified in G1 (p<0.05, OR=1.94, 95% CI=1.04–3.63) and G2 (p<0.001, OR=3.68, 95% CI=1.94–3.07) compared with SWOC. Regarding genotype GA of rs361525, it has been associated when comparing COPD-BB vs BBES (p=0.0079, OR=5.99, 95% CI=1.38–53.98). Conclusion: The heterozygous genotype GA of polymorphisms rs1800629 and rs361525 in the TNF promoter are associated with the risk of COPD. Keywords: COPD, biomass burning, SNP, TNF

19 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GPGloria Pérez-Rubio
Gloria Pérez-Rubio
ARAlejandra Ramírez-Venegas
Alejandra Ramírez-Venegas
VDValeri Noé Díaz
Valeri Noé Díaz
LGLeonor García Gómez
Leonor García Gómez
KFKarina Elvira Fabián
Karina Elvira Fabián
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Genes encoding the receptors involved in the dopaminergic and serotonergic pathways are potential candidates in the mechanisms of nicotine addiction. To identify genetic variants in the promoter regions and exons of the DRD4 and HTR2A genes associated with tobacco smoking and the degree of nicotine addiction in Mexican mestizos. The study included 438 non-smokers (NS) and 1,157 current smokers, ranked based on their consumption of cigarettes per day (cpd): 574 heavy smokers (HS, >20 cpd) and 583 light smokers (LS, 1–10 cpd). Genotyping was performed for 4 and 8 single nucleotide polymorphisms (SNPs) in the DRD4 and HTR2A genes, respectively. The C allele of rs1800955 in DRD4 was found to be associated with cigarette smoking in the HS vs. NS and LS vs. NS comparisons (p = 2.34E-03 and p = 1.13E-03, respectively); the association was maintained in the homozygous CC genotype (p = 5.00E-04 and p = 2.00E-04, respectively). The T allele of rs6313 in HTR2A was significantly associated with cigarette smoking and a greater degree of nicotine addiction (p = 4.77E-03, OR = 1.55); the association was maintained in the homozygous genotype (TT) (p = 4.90E-03, OR = 1.96). The A allele of rs6313 was associated with cigarette smoking in the HS vs. NS comparison (p = 1.53E-02, OR = 1.36); the risk was nearly doubled in the homozygous AA genotype (p = 1.30E-03, OR = 1.83) compared with the heterozygous GA genotype (OR = 1.38). Among Mexican mestizos, the C allele of rs1800955 in the DRD4 gene and the A allele of rs6311 in the HTR2A gene are associated with cigarette smoking, whereas the T allele of rs6313 in HTR2A is associated with cigarette smoking and the degree of nicotine addiction.

8 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
KNKarol Jazmin Nava-Quiroz
Karol Jazmin Nava-Quiroz
JRJorge Rojas-Serrano
Jorge Rojas-Serrano
Gloria Pérez RubioGloria Pérez Rubio
Gloria Pérez Rubio
Ivette Buendia-RoldanIvette Buendia-Roldan
Ivette Buendia-Roldan
MMMayra Mejía
Mayra Mejía
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Around 50% of rheumatoid arthritis (RA) patients show some extra-articular manifestation, with the lung a usually affected organ; in addition, the presence of anti-citrullinated protein antibodies (ACPA) is a common feature, which is caused by protein citrullination modifications, catalyzed by the peptidyl arginine deiminases (PAD) enzymes. We aimed to identify single nucleotide variants (SNV) in PADI2 and PADI4 genes (PAD2 and PAD4 proteins, respectively) associated with susceptibility to interstitial lung disease (ILD) in RA patients and the PAD2 and PAD4 levels. Material and methods: 867 subjects were included: 118 RA-ILD patients, 133 RA patients, and 616 clinically healthy subjects (CHS). Allelic discrimination was performed in eight SNVs using qPCR, four in PADI2 and four in PADI4. The ELISA technique determined PAD2 and PAD4 levels in serum and bronchoalveolar lavage (BAL) samples, and the population structure was evaluated using 14 informative ancestry markers. Results: The rs1005753-GG (OR = 4.9) in PADI2 and rs11203366-AA (OR = 3.08), rs11203367-GG (OR = 2.4) in PADI4 are associated with genetic susceptibility to RA-ILD as well as the ACTC haplotype (OR = 2.64). In addition, the PAD4 protein is increased in RA-ILD individuals harboring the minor allele homozygous genotype in PADI4 SNVs. Moreover, rs1748033 in PADI4, rs2057094, and rs2076615 in PADI2 are associated with RA susceptibility. In conclusion, in RA patients, single nucleotide variants in PADI4 and PADI2 are associated with ILD susceptibility. The rs1748033 in PADI4 and two different SNVs in PADI2 are associated with RA development but not ILD. PAD4 serum levels are increased in RA-ILD patients.

6 March 2017
Verified
Journal Article
Open access
LLLuis López-Flores
Luis López-Flores
GPGloria Pérez-Rubio
Gloria Pérez-Rubio
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia
Tobacco consumption has become a major public health issue, which has motivated studies to identify and understand the biological processes involved in the smoking behavior for prevention and smoking cessation treatments. CYP2A6 has been identified as the main gene that codifies the enzyme that metabolizes nicotine. Many alleles have been identified after the discovery of CYP2A6, suggesting a wide interethnic variability and a diverse smoking behavior of the allele carrying individuals. The main purpose of this review is to update and highlight the effects of the CYP2A6 gene variability related to tobacco consumption reported from diverse human populations. The review further aims to consider CYP2A6 in future studies as a possible genetic marker for the prevention and treatment of nicotine addiction. Therefore, we analyzed several population studies and their importance at addressing and characterizing a population using specific parameters. Our efforts may contribute to a personalized system for detecting, preventing and treating populations at a higher risk of smoking to avoid diseases related to tobacco consumption.

1 April 2019 in Gene
Verified
Journal Article
Closed access
GPGloria Pérez-Rubio
Gloria Pérez-Rubio
LLLuis López-Flores
Luis López-Flores
SGSalvador García-Carmona
Salvador García-Carmona
LGLeonor García-Gómez
Leonor García-Gómez
VNValeri Noé-Díaz
Valeri Noé-Díaz
Ramcés Falfán-ValenciaRamcés Falfán-Valencia
Ramcés Falfán-Valencia